Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline
Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline · The Wall Street Journal

In This Article:

The pharma giant wants to refreshen its portfolio after some of its internal development programs disappointed in clinical trials.